Clinical trials: ST-elevation Myocardial Infarction (STEMI)
Myocardial Infarction
Safety of Nitroglycerin for Field Treatment of STEMI
The purpose of this study is to quantify the risk of hypotension due to field treatment with nitroglycerin in patients with ST-elevation myocardial infarction, particularly right ventricular infarcts, and secondarily to evaluate…
- Trial name
- NCT02407002
- Where
- 3 sites in United States
- Volunteers
- 940 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
ST Elevation Myocardial Infarction
Clinical Trial in Patients Who Have Suffered a Heart Attack and Who Have Undergone Catheterization Treated With Levosimendan
The disease under study is acute coronary syndrome with ST segment elevation, defined as patients presenting chest pain of anginal characteristics of more than 20 minutes of duration, with changes in the electrocardiogram…
- Trial name
- LEVOCEST (NCT03699215)
- Testing
- Levosimendan
- Where
- Spain
- Volunteers
- 184 people
- Sponsor
- Hospital Universitario de Canarias
Non STEMI, Unstable Angina
Safety and Efficacy of CMX-2043 for Protection of the Heart and Kidneys in Subjects Undergoing Coronary Angiography
The objective of this study is to evaluate CMX-2043 for prevention of renal and cardiac injury associated with coronary angiography in patients with acute coronary syndrome (ACS), but excluding ST-elevation myocardial infarction…
- Trial name
- CARIN (NCT02103959)
- Testing
- CMX-2043
- Volunteers
- 361 people
- Sponsor
- Ischemix, LLC
Acute Myocardial Infarction
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.
- Trial name
- PARADISE-MI (NCT02924727)
- Testing
- LCZ696 (sacubitril/valsartan), Ramipril, Valsartan
- Where
- 486 sites in United States, Argentina and 39 more
- Volunteers
- 5,669 people
- Sponsor
- Novartis Pharmaceuticals
ST-segment Elevation Myocardial Infarction (STEMI), Total Occlusion of Coronary Artery
Use of Export in Primary Percutaneous Coronary Intervention
Aim of this single center randomized open label trial with blinded in-hospital outcomes assessment is designed with aim to compare manual thrombus aspiration followed by percutaneous coronary intervention (PCI) strategy with PCI…
- Conditions
- ST-segment Elevation Myocardial Infarction (STEMI), Total Occlusion of Coronary Artery, Primary Percutaneous Coronary Intervention
- Trial name
- EPISOO (NCT05510661)
- Testing
- Export Catheter, Balloon catheter
- Where
- Pakistan
- Volunteers
- 300 people
- Sponsor
- National Institute of Cardiovascular Diseases, Pakistan
Non ST Elevation Myocardial Infarction, Unstable Angina
Conservative Non-Invasive Versus Routine Invasive Management in Coronary Artery Bypass Surgery Patients with Non ST Elevation Elevation Acute Coronary Syndrome
Background: Most coronary artery bypass grafts (CABG) are diseased or blocked within 10 years of surgery meaning CABG survivors have an ever increasing risk of recurrent angina, heart attack and death.
- Trial name
- CABG-ACS (NCT01895751)
- Testing
- Invasive management
- Where
- 5 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- NHS National Waiting Times Centre Board
Acute Coronary Syndrome, Angina Pectoris
Diagnostic Performance of Artificial Intelligence Algorithms in Prediction of Acute Coronary Syndrome Based on White Blood Cell Properties
The goal of this observational study is to evaluate whether artificial intelligence (AI) algorithms can predict or exclude acute coronary syndrome (ACS) in adults using data generated by routine hematology testing.
- Conditions
- Acute Coronary Syndrome, Angina Pectoris, NSTEMI - Non-ST Segment Elevation MI, STEMI - ST Elevation Myocardial Infarction
- Trial name
- NCT06384846
- Where
- Austria
- Volunteers
- 3,350 people, healthy volunteers welcome
- Sponsor
- RobotDreams GmbH
Acute Coronary Syndrome, Unstable Angina
Treatment of ACuTe Coronary Syndromes With Low-dose colchICine
This trial is designed to evaluate whether low-dose colchicine, in addition to standard treatment recommended by guidelines, further reduces the risk of major adverse cardiovascular events in patients with acute coronary…
- Conditions
- Acute Coronary Syndrome, Unstable Angina, ST Elevation Myocardial Infarction, Non ST Segment Elevation Myocardial Infarction
- Trial name
- NCT06215989
- Testing
- Colchicine Pill
- Where
- China
- Volunteers
- 6,574 people
- Sponsor
- Beijing Anzhen Hospital
Acute Myocardial Infarction (AMI), STEMI - ST Elevation Myocardial Infarction (MI)
Effect of Dapagliflozin Administration on the Apoptosis Levels of Patients With Acute Myocardial Infarction
The currently known Sodium-Glucose Transporter 2 (SGLT-2) inhibitors are recognized not only for their effects on improving intravascular glucose levels but also for their cardioprotective effects, including improvements in…
- Conditions
- Acute Myocardial Infarction (AMI), STEMI - ST Elevation Myocardial Infarction (MI), NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)
- Trial name
- DAPOPTOSIS-MI (NCT06615674)
- Testing
- Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia
- Where
- Indonesia
- Volunteers
- 40 people
- Sponsor
- Yoga Yudhistira
Acute Coronary Syndrome
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Losmapimod is a new anti-inflammatory medication which potentially may benefit patients with Acute Coronary Syndrome, (ACS), a condition which includes heart attack.
- Trial name
- LATITUDE (NCT02145468)
- Testing
- Losmapimod 7.5 mg twice daily, Standard therapy
- Where
- 341 sites in United States, Argentina and 32 more
- Volunteers
- 3,503 people
- Sponsor
- GlaxoSmithKline
STEMI, Dyslipidemias
The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients
Patients with acute coronary syndromes (ACS) have an increased risk of recurrent ischemic events, particularly during the first year following the index event, which is mainly due to unattended risk factors and/ or poor…
- Trial name
- NCT05579418
- Testing
- Evolocumab
- Volunteers
- 350 people
- Sponsor
- Hamad Medical Corporation
Interventional, Cardiology
France PCI Registry : National Observatory of Interventional Cardiology
Rigorous clinical practice assessment is a key factor to improve patient's care and prognosis in interventional cardiology (IC).
- Conditions
- Interventional, Cardiology, Angioplasty, Coronary
- Trial name
- NCT02778724
- Where
- 15 sites in France
- Volunteers
- 40,000 people
- Sponsor
- Club Régional des Angioplasticiens de la région Centre
NSTEMI - Non-ST Segment Elevation MI
Clinical and Economic Outcomes of High Sensitivity Troponin for no ST Elevation Myocardial Infarction in Patients With Chest Pain in Emergency Departments in Italy-An Observational Study
Myocardial infarction is one of the leading causes of death and disability worldwide. In addition to standard diagnostic methods, it has been shown that high-sensitivity cardiac troponin assays allow greater sensitivity in the…
- Trial name
- NCT03489603
- Where
- Italy
- Volunteers
- 2,913 people
- Sponsor
- Marco Marchetti
ST-segment Elevation Myocardial Infarction (STEMI)
Bivalirudin with Prolonged Infusion During PCI Versus Heparin After Fibrinolytic Therapy
This multicenter, randomized controlled trial in China aims to enroll 2,400 patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) within 24 hours post-fibrinolysis.
- Trial name
- BRIGHT-FIT (NCT06861374)
- Testing
- Bivalirudin, Unfractionated heparin
- Volunteers
- 2,400 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
No-Reflow Phenomenon, STEMI - ST Elevation Myocardial Infarction
NGAL and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial Infarction
The aim of this study is to investigate the association between NGAL plasma levels in ST-elevation myocardial infarction and the no-reflow phenomenon, adverse events during hospitalization and at 30-day follow-up.
- Trial name
- NCT03264859
- Testing
- NGAL levels early and post STEMI
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Sheba Medical Center
Acute Coronary Syndromes, STEMI
Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX
This protocol describes a study to compare intended trans-radial versus trans-femoral intervention and bivalirudin monotherapy versus current European standard of care consisting of unfractionated heparin (UFH) plus provisional…
- Conditions
- Acute Coronary Syndromes, STEMI, NSTEMI
- Trial name
- MATRIX (NCT01433627)
- Testing
- trans-radial and short-term bivalirudin, trans-radial and long-term bivalirudin infusion, trans-radial and standard of care pharmacology
- Where
- 62 sites in Italy
- Volunteers
- 7,200 people
- Sponsor
- Italian Society of Invasive Cardiology
Coronary Artery Disease, ST Elevation Myocardial Infarction
Prognostic Implications of AccuFFRangio-guided PCI in STEMI
This is a prospective, single-center clinical trial. AccuFFRangio (ArteryFlow Technology Co., Ltd., Hangzhou, China) is a novel method for evaluating the functional significance of coronary stenosis by computing the pressure in…
- Trial name
- NCT05209503
- Testing
- AccuFFRangio-guided strategy, Angiography-guided strategy
- Volunteers
- 500 people
- Sponsor
- Wuhan Asia Heart Hospital
Coronary Artery Disease, Myocardial Infarction
Randomized Study to Assess the Effect of ThRombus Aspiration on Flow Area in STEMI Patients
The purpose of the study it to evaluate whether primary percutaneous coronary intervention (primary PCI) with a new thrombectomy device as compared to primary PCI without thrombectomy increases minimal flow area after stenting…
- Conditions
- Coronary Artery Disease, Myocardial Infarction, STEMI
- Trial name
- TROFI (NCT01271361)
- Testing
- primary PCI with thrombectomy, primary PCI without thrombectomy
- Where
- 5 sites in Denmark, France and 2 more
- Volunteers
- 140 people
- Sponsor
- Terumo Europe N.V.
NSTEMI - Non-ST Segment Elevation MI, Unstable Angina
A Multicenter Study on Early Diagnosis of NSTE-ACS Patients Based on Machine Learning Model
Early diagnosis of NSTEMI and UA patients is mainly through the construction of machine learning model.
- Trial name
- NCT04682756
- Testing
- The model of machine learning
- Where
- China
- Volunteers
- 2,500 people
- Sponsor
- First Affiliated Hospital of Xinjiang Medical University
NSTEMI
Incidence of Occluded Culprit Arteries and Impact of Coronary Collaterals on Outcome in Patients With NSTEMI
It is assumed that patients with non-ST-elevation myocardial infarctions (NSTEMI) showing an infero- or posterolateral occluded culprit artery (OCA) during diagnostic angiography frequently elude standard 12-lead…
- Trial name
- NCT01159366
- Testing
- percutaneous coronary intervention
- Where
- Germany
- Volunteers
- 602 people
- Sponsor
- University of Jena
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.